New Telehealth Firm Offers $86 Weight-Loss Drugs Amid FDA Scrutiny

NEW YORK, NY – May 19, 2026 – A new telehealth company, Ozari Health, has launched a nationwide platform offering access to compounded versions of popular GLP-1 medications, including semaglutide and tirzepatide, at prices starting as low as $86 per month. The move aims to disrupt a market dominated by high-cost brand-name drugs like Ozempic and Wegovy, but it also steps into a complex and increasingly scrutinized regulatory landscape for compounded pharmaceuticals.

Ozari Health's model allows patients to complete an online health assessment, consult with a licensed provider, and, if deemed appropriate, receive a prescription for medications that are shipped directly to their homes. The company promises a transparent, no-hidden-fee structure and also provides access to the branded versions of the drugs, such as Wegovy, Ozempic, Mounjaro, and Zepbound, for those with insurance coverage or who prefer the FDA-approved options.

The Promise of Accessibility

The appeal of services like Ozari Health is rooted in the dramatic success of GLP-1 agonists and the equally dramatic cost. These drugs, originally developed for diabetes management, have proven to be revolutionary for weight loss. The SURMOUNT-1 clinical trial, for instance, showed that participants taking tirzepatide achieved an average weight reduction of up to 20.9% over 72 weeks. Another study, SURMOUNT-5, directly compared it to semaglutide, finding tirzepatide led to greater weight loss.

This high efficacy, however, comes with a prohibitive price tag for many. Brand-name versions can cost well over $1,000 per month without insurance, creating a significant barrier to access. Ozari Health positions itself as a solution to this affordability crisis. By offering compounded semaglutide starting at $86 and tirzepatide at $120, the company is tapping into a vast, underserved market of individuals seeking these transformative treatments without the financial burden.

"We spent months watching people we care about try to figure this out on their own, researching pharmacies, comparing prices, trying to determine what was actually legitimate and safe," said Lucy, Co-Founder of Ozari Health, in the company's launch announcement. "Ozari exists because that process is way harder than it needs to be. We built the thing we wish our families had found on day one."

This mission is reflected in the platform's design, which emphasizes user choice and support. Unlike some telehealth services that are tied to a single pharmacy, Ozari Health allows patients to choose from a network of partners, including Hallandale Pharmacy and VialsRX, with more expected to be added. The company also highlights its commitment to personalized customer service, a direct response to the often-impersonal nature of larger digital health platforms.

Navigating a Regulatory Minefield

While the promise of affordable access is compelling, the use of compounded medications places Ozari Health and its competitors in a legally and medically complex environment. Compounded drugs are custom-made medications prepared by a pharmacist for an individual patient. Crucially, they are not approved by the Food and Drug Administration (FDA), meaning they have not undergone the same rigorous testing for safety, efficacy, and quality as their branded counterparts.

The FDA has issued multiple warnings regarding compounded GLP-1 drugs. The agency has expressed serious concerns about the potential for contamination, incorrect dosages, and the use of unapproved active pharmaceutical ingredients (APIs). In some cases, drugs marketed as compounded semaglutide were found to contain different, unverified salt forms of the active ingredient, raising questions about their safety and effectiveness.

Previously, compounding pharmacies could legally produce versions of these drugs because the branded versions were on the FDA's official drug shortage list. However, as of early 2025, both semaglutide and tirzepatide are no longer listed as being in shortage. This has prompted the FDA to take a firmer stance, announcing in April 2026 that it intends to restrict the use of GLP-1 APIs for non-approved compounded products and crack down on misleading advertising that suggests these versions are equivalent to the FDA-approved drugs.

This regulatory shift puts companies offering compounded GLP-1s in a precarious position. Some industry experts suggest that pharmacies may continue to operate by creating "custom formulations"—for example, by adding a vitamin like B12 to the drug—to argue that their product is not a direct copy of a commercially available medication. However, this practice remains a legal gray area and does not change the fact that the resulting product is not FDA-approved.

The Challenge of Trust and Transparency

For patients, this landscape can be confusing and risky. The quality of compounded medications can vary significantly between pharmacies. Ozari's listed partner, Hallandale Pharmacy, for instance, has received mixed public reviews and was the subject of an FDA warning letter in 2020 regarding sterile compounding practices. While Ozari Health states it partners with "trusted" and licensed pharmacies, the ultimate responsibility for due diligence often falls on the consumer.

In an effort to build trust, Ozari Health highlights its LegitScript verification. LegitScript is a third-party certification service that vets healthcare merchants to ensure they comply with applicable laws and regulations. This certification is a requirement for advertising on major platforms like Google and Meta and provides a layer of assurance that a company is operating legitimately. However, it does not replace FDA approval of the drugs themselves.

As the market for weight loss medications continues to explode, companies like Ozari Health are filling a critical gap between demand and affordability. Their model offers a potential lifeline for individuals who cannot access or afford brand-name treatments. Yet, this access comes with inherent risks and operates within a shifting regulatory environment. The success of Ozari and similar platforms will depend not only on their ability to deliver on promises of low cost and good service but also on their capacity to navigate the complex legal and ethical challenges of providing unapproved, albeit highly sought-after, medications to the public.